Literature DB >> 29368979

Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia.

Luke A Jelen1,2, Sinead King1, Paul G Mullins3, James M Stone1.   

Abstract

Abnormalities of the glutamate system are increasingly implicated in schizophrenia but their exact nature remains unknown. Proton magnetic resonance spectroscopy (1H-MRS), while fundamental in revealing glutamatergic alterations in schizophrenia, has, until recently, been significantly limited and thought to only provide static measures. Functional magnetic resonance spectroscopy (fMRS), which uses sequential scans for dynamic measurement of a range of brain metabolites in activated brain areas, has lately been applied to a variety of task or stimulus conditions, producing interesting insights into neurometabolite responses to neural activation. Here, we summarise the existing 1H-MRS studies of brain glutamate in schizophrenia. We then present a comprehensive review of research studies that have utilised fMRS, and lastly consider how fMRS methods might further the understanding of glutamatergic abnormalities in schizophrenia.

Entities:  

Keywords:  Functional magnetic resonance spectroscopy(fMRS); Glx; glutamate; glutamine; schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 29368979     DOI: 10.1177/0269881117747579

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  12 in total

Review 1.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

2.  Simultaneous metabolic and functional imaging of the brain using SPICE.

Authors:  Rong Guo; Yibo Zhao; Yudu Li; Yao Li; Zhi-Pei Liang
Journal:  Magn Reson Med       Date:  2019-07-11       Impact factor: 4.668

3.  Memory recall involves a transient break in excitatory-inhibitory balance.

Authors:  Renée S Koolschijn; Anna Shpektor; William T Clarke; I Betina Ip; David Dupret; Uzay E Emir; Helen C Barron
Journal:  Elife       Date:  2021-10-08       Impact factor: 8.140

4.  Dopamine and glutamate in schizophrenia: biology, symptoms and treatment.

Authors:  Robert A McCutcheon; John H Krystal; Oliver D Howes
Journal:  World Psychiatry       Date:  2020-02       Impact factor: 49.548

5.  Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.

Authors:  Matthijs G Bossong; Mathilde Antoniades; Matilda Azis; Carly Samson; Beverley Quinn; Ilaria Bonoldi; Gemma Modinos; Jesus Perez; Oliver D Howes; James M Stone; Paul Allen; Philip McGuire
Journal:  JAMA Psychiatry       Date:  2019-02-01       Impact factor: 21.596

Review 6.  Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia.

Authors:  Eduard Parellada; Patricia Gassó
Journal:  Transl Psychiatry       Date:  2021-05-06       Impact factor: 6.222

Review 7.  The potential of 1H-MRS in CNS drug development.

Authors:  Alice Egerton
Journal:  Psychopharmacology (Berl)       Date:  2019-09-05       Impact factor: 4.530

8.  Fearful dogs have increased plasma glutamine and γ-glutamyl glutamine.

Authors:  Jenni Puurunen; Katriina Tiira; Katariina Vapalahti; Marko Lehtonen; Kati Hanhineva; Hannes Lohi
Journal:  Sci Rep       Date:  2018-10-29       Impact factor: 4.379

Review 9.  Astrocytic Regulation of Glutamate Transmission in Schizophrenia.

Authors:  Yu-Ying Mei; Dong Chuan Wu; Ning Zhou
Journal:  Front Psychiatry       Date:  2018-11-06       Impact factor: 4.157

10.  Influence of Repetitive Transcranial Magnetic Stimulation on Human Neurochemistry and Functional Connectivity: A Pilot MRI/MRS Study at 7 T.

Authors:  Heidi Gröhn; Bernadette T Gillick; Ivan Tkáč; Petr Bednařík; Daniele Mascali; Dinesh K Deelchand; Shalom Michaeli; Gregg D Meekins; Michael J Leffler-McCabe; Colum D MacKinnon; Lynn E Eberly; Silvia Mangia
Journal:  Front Neurosci       Date:  2019-11-27       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.